Evidence map›Paper›PMID 39434171›Full record

ArticleTrials2024

A study of intersphincteric resection rate following robotic-assisted total mesorectal excision versus laparoscopic-assisted total mesorectal excision for patients with middle and low rectal cancer: study protocol for a multicenter randomized clinical trial.

Yuchen Guo, Liang He, Weidong Tong, Zhaocheng Chi, Shuangyi Ren, Binbin Cui, Quan Wang

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06105203 (A Multicenter Randomized Clinical Trial to Assess the Advantages of Robotic Total Mesorectal Excision in Preserving External Sphincter in Patients with Middle and Low Rectal Cancer.), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06105203 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

A Multicenter Randomized Clinical Trial to Assess the Advantages of Robotic Total Mesorectal Excision in Preserving External Sphincter in Patients with Middle and Low Rectal Cancer.

TypeinterventionalSponsorThe First Hospital of Jilin UniversityRan2025 to 2031Enrolled1,026ConditionsTotal Mesorectal Excision, Rectal Neoplasms, Robotic Surgical Procedures, LaparoscopyArmsRobotic-assisted total mesorectal excision, laparoscopic-assisted total mesorectal excision
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuchen GuoDepartment of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Liang HeDepartment of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Weidong TongDaping Hospital and the Research Institute of Surgeryof the, Third Military Medical University , Chongqing, China.
Zhaocheng ChiJilin Provincial Tumor Hospital, Changchun, China.
Shuangyi RenSecond Affiliated Hospital of Dalian Medical University, Dalian, China.
Binbin CuiTumor Hospital of Harbin Medical University, Harbin, China.
Quan WangDepartment of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China. wquan@jlu.edu.cn.ORCID http://orcid.org/0000-0001-6727-1508

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRobotic-assisted complete mesorectal excision (RATME) is increasingly being used by colorectal surgeons. Most surgeons consider RATME a safe method, and believe it can facilitate total mesorectal excision (TME) in rectal cancer, and may potentially have advantages over intersphincteric resection (ISR) and anus preservation. Therefore, this trial was designed to investigate whether RATME has technical advantages and can increase the ISR rate compared with laparoscopic-assisted TME (LATME) in patients with middle and low rectal cancer. METHODS AND ANALYSIS: This is a multicenter, superiority, randomized controlled trial designed to compare RATME and LATME in middle and low rectal cancer. The primary endpoint is the ISR rate. The secondary endpoints are coloanal anastomosis (CAA) rate, conversion to open surgery, conversion to transanal TME (TaTME), abdominoperineal resection (APR) rate, postoperative morbidity and mortality within 30 days, pathological outcomes, long-term survival outcomes, functional outcomes, and quality of life. In addition, certain measurements will be conducted to ensure quality and safety, including centralized photography review and semiannual assessment. DISCUSSION: This trial will clarify if RATME improves ISR and promotes anus preservation in patients with mid- and low-rectal cancer. Furthermore, this trial will provide evidence on the optimal treatment strategies for RATME and LATME in patients with mid- and low-rectal cancer regarding improved operational safety.

trial registrationClinicalTrials.gov NCT06105203. Registered on October 27, 2023.

Indexed as

Anal CanalLaparoscopyMulticenter Studies as TopicRectal NeoplasmsRobotic Surgical ProceduresAdultEquivalence Trials as TopicFemaleHumansMaleMiddle AgedPostoperative ComplicationsProctectomyQuality of LifeRandomized Controlled Trials as TopicRectumIntersphincteric resectionLaparoscopyRectal cancerRobotTotal mesorectal excision

Identifiers

PMID39434171
PMCPMC11495107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.